Key Insights Institutions' substantial holdings in Oruka Therapeutics implies that they have significant influence ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today. The company’s shares closed ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) and keeping the price target at ...

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus rating of “Buy” from the eight ...

Oruka Therapeutics, Inc. ( (ORKA)) has released its Q3 earnings. Here is a breakdown of the information Oruka Therapeutics, Inc. presented to its investors. Oruka Therapeutics, Inc. is a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases ...

Oruka Therapeutics, Inc. (NASDAQ:ORKA), a biopharmaceutical company focusing on in vitro and in vivo diagnostic substances, has filed an 8-K with the Securities and Exchange Commission to announce ...

Oruka Therapeutics, Inc. (NASDAQ:ORKA), a biopharmaceutical company focusing on in vitro and in vivo diagnostic substances, has filed an 8-K with the Securities and Exchange Commission to announce the ...

Oruka Therapeutics, Inc., a company specializing in diagnostic substances, announced the approval of key proposals at its Special Meeting of Stockholders held on November 14, 2024. The ...